Drug intelligence / Profile preview

dexamethasone + salbutamol

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Inhalation, Intramuscular
01

Overview

**dexamethasone + salbutamol** is a combination therapy consisting of two drugs: dexamethasone, a synthetic corticosteroid, and salbutamol (also known as albuterol), a selective beta-2 adrenergic receptor agonist. Dexamethasone acts by suppressing inflammation and immune responses, stabilizing cell membranes, and reducing airway edema. Salbutamol relaxes bronchial smooth muscle through stimulation of beta-2 receptors, leading to bronchodilation and rapid relief of bronchospasm. This combination is primarily used in the treatment of acute wheezing, asthma exacerbations, and lower respiratory conditions in infants and children where both airway inflammation and bronchospasm are contributing factors. Evidence suggests that the combination may offer improved efficacy due to possible synergistic effects: corticosteroids may potentiate beta-2 receptor responsiveness, resulting in more rapid and marked clinical improvement in acute episodes compared to monotherapy with either agent[1][3][9].

Other names
albuterol + dexamethasone
02

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on dexamethasone + salbutamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + salbutamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call